CPX treatment leads to CRC cell cycle arrest at G1 phase through decreasing the expression of Cyclin A, Cyclin B1, Cyclin D1, CDK4, CDK6, as well as inhibiting the activation of CDKs and reducing the level of p-Rb/Rb, thereby suppressing CRC cell proliferation. Here, CDK6 is linked to colorectal carcinoma.